ARID2 and melanoma: Additionally, Fukumoto et al. had previously demonstrated that T-cells CD8+ and IFN-γ infiltration levels increased significantly in ARID2 mutation-mice melanoma cells following anti-PD-L1 treatment43, further strengthening the argument that ARID2 mutation patients may be ideal candidates for immunotherapy.